News

Medpace (NASDAQ:MEDP) Beats Expectations in Strong Q1 But Stock Drops

Clinical research company Medpace Holdings (NASDAQ:MEDP) announced better-than-expected revenue in Q1 CY2025, with sales up 9.3% year on year to $558.6 million. The company’s full-year revenue guidance of $2.19 billion at the midpoint came in 1.9% above analysts’ estimates. Its GAAP profit of $3.67 per share was 20.8% above analysts’ consensus estimates.

How stocks, bonds and other markets have fared so far in 2025

Global financial markets have been turned upside down this year by President Donald Trump's burgeoning trade war. Markets are not in full panic, but the double-digit declines in major U.S. stock indexes are testing nerves. U.S. markets had been on a two-year tear coming into 2025, though many believed that stock prices had become overinflated.